An Open-label Study to Assess the Safety of Repeat Administration of FX006 to Patients With Osteoarthritis of the Knee
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 26 Apr 2018
At a glance
- Drugs Triamcinolone (Primary)
- Indications Musculoskeletal pain
- Focus Adverse reactions
- Sponsors Flexion Therapeutics
- 26 Apr 2018 Results presented in the Flexion Therapeutics media release.
- 26 Apr 2018 According to a Flexion Therapeutics media release, interim data from this trial will be presented at the Osteoarthritis Research Society International (OARSI) (April 2018) World Congress.
- 08 Jan 2018 According to a a Flexion Therapeutics media release, full study results are expected in the third quarter of 2018.